Remestemcel-L ( DrugBank: Remestemcel-L )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
96クローン病2
97潰瘍性大腸炎1

96. クローン病


臨床試験数 : 2,442 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01233960
(ClinicalTrials.gov)
November 29, 20102/11/2010Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's DiseaseA Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's DiseaseCrohn's DiseaseDrug: adult human mesenchymal stem cellsMesoblast, Inc.NULLCompleted18 Years70 YearsAll73Phase 3United States;Australia;New Zealand
2NCT01510431
(ClinicalTrials.gov)
July 20109/1/2012Safety and Treatment Outcome Study of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's DiseaseAn Open-label Compassionate Treatment Protocol to Evaluate the Safety and Treatment Outcomes of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's DiseaseCrohn's DiseaseDrug: PROCHYMAL (remestemcel-L)Mesoblast, Inc.NULLNo longer available18 Years70 YearsAllUnited States

97. 潰瘍性大腸炎


臨床試験数 : 2,630 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04543994
(ClinicalTrials.gov)
November 10, 20203/9/2020Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)A Phase IB/IIA Study of Remestemcel-L, an ex Vivo Culture-expanded Adult Allogeneic Bone Marrow Derived Mesenchymal Stem Cell Product, for the Treatment of Medically Refractory Ulcerative ColitisUlcerative ColitisDrug: Remestemcel-L;Other: PlaceboThe Cleveland ClinicMesoblast, Inc.Recruiting18 Years75 YearsAll24Phase 1/Phase 2United States